AGIOS PHARMACEUTICALS, INC. 10-Q

Item 5. Other Information (c) Director and Officer Trading Arrangements A significant portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other of our securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons. Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information. The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”) or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K): Name (Title) Action Taken (Date of Action) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities Sarah Gheuens, M.D., Ph.D. ( Chief Medical Officer, Head of Research & Development ) Adoption ( May 1, 2026 ) Rule 10b5-1 trading arrangement Sale Through and including August 2, 2027 Up to 151,653 shares Cecilia Jones ( Chief Financial Officer ) Adoption ( May 1, 2026 ) Rule 10b5-1 trading arrangement Sale Through and including August 2, 2027 Up to 34,076 shares Tsveta Milanova ( Chief Commercial Officer ) Adoption ( May 1, 2026 ) Rule 10b5-1 trading arrangement Sale Through and including July 30, 2027 Up to 9,403 shares 57 Table of Contents Item 6. Exhibits Incorporated by Reference Exhibit Number Description of Exhibit Form File Number Date of Filing Exhibit Number Filed Herewith 3.1 Restated Certificate of Incorporation 8-K 001-36014 July 30, 2013 3.1 3.2 Third Amended and Restated By-Laws 8-K 001-36014 March 3, 2023 3.1 10.1 Agios Pharmaceuticals, Inc. 2023 Stock Incenti ve Plan, as amended S-8 333-296899 June 18, 2026 99.1 31.1 Certification of principal executive officer pursuant to Rule 13a 14(a)/15d - 14(a) of the Securities Exchange Act of 1934, as amended. X 31.2 Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended. X 32.1* Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 32.2* Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document X 101.SCH XBRL Taxonomy Extension Schema Document X 101.CAL XBRL Taxonomy Calculation Linkbase Document X 101.DEF XBRL Taxonomy Extension Definition Linkbase Document X 101.LAB XBRL Taxonomy Label Linkbase Document X 101.PRE XBRL Taxonomy Presentation Linkbase Document X 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS) X * This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing. 58 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AGIOS PHARMACEUTICALS, INC. July 30, 2026 By: /s/ Brian Goff Brian Goff Chief Executive Officer (principal executive officer) July 30, 2026 By: /s/ Cecilia Jones Cecilia Jones Chief Financial Officer (principal financial officer) 59